Plain-English translation of NCT05147792 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atrial Fibrillation research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new device called the CLAAS system that is placed inside the heart to help prevent strokes in people with atrial fibrillation (an irregular heartbeat). The device works by blocking off a small pouch in the heart where blood clots can form. Researchers want to see if this new treatment works as well as two other devices that are already being used for the same purpose.
People with atrial fibrillation have a higher risk of stroke because their irregular heartbeat can cause blood clots to form in the heart. While blood thinner medications can help prevent these clots, some patients cannot take them safely or for long periods. This trial exists to see if the CLAAS device offers a safe alternative way to prevent strokes in these patients.
If you qualify and enroll, you will be randomly assigned to receive either the new CLAAS device or one of the two existing devices. A cardiologist will implant your assigned device through a small catheter (thin tube) inserted through a vein in your leg — you will not need open-heart surgery. After the procedure, you will take blood thinner medication for several weeks, then move to aspirin or similar blood-thinning medications. You will be followed closely for 5 years with regular clinic visits and heart imaging to make sure the device is working well and to watch for any side effects.
AI-generated summary from trial data · Aug 24, 2026 · Not medical advice
United States